ArticleFrontiers in pediatrics2026
Refractory postoperative eczematous dermatitis after total auricular reconstruction, temporally associated with povidone-iodine: a case report.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 9 year and 4 month old female patient underwent stage I and stage II total auricular reconstruction using the Nagata technique. Following each procedure, she developed localized postoperative eczematous dermatitis involving the reconstructed auricle (and, after stage II, also the abdominal donor site), most consistent with contact dermatitis (allergic vs. irritant) on compromised postoperative skin and temporally associated with local povidone-iodine exposure. Initial management with saline cleansing/irrigation, antihistamines, topical therapy, and systemic antibiotics/corticosteroids produced minimal improvement. Two short, tapering courses of oral tacrolimus were therefore administered (1 mg twice daily initially; total course 17 days for each episode), with clinical improvement noted by day 5 and complete clearance by day 13 during the first course, and improvement by day 3 with complete clearance by day 10 during the second course. Blood pressure and renal/hepatic function were monitored on tacrolimus day 5 and day 10 during both courses and remained within normal limits; tacrolimus trough levels were not measured. No adverse events or infections occurred, and no recurrence was observed at 3-month follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.